|
|
Article: Riverside Partners Portfolio Company J-Pac Names New CEO.
- Article from:
- Biotech Week
- Article date:
- July 30, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Riverside Partners, a Boston based private equity firm focusing on healthcare and technology businesses, is pleased to announce that The J-Pac and Doyen Medipharm Group ("JPDM" or the "Company"), a leader in contract manufacturing and packaging machinery for the medical device and pharmaceutical industries, has named Dr. P. Richard Eagling as the Company's new Chief Executive Officer and a board member. Richard succeeds Bill McLaughlin, who led JPDM successfully for the past 8 years. Mr. McLaughlin will remain active with the Group as its Vice Chairman and a member of the board of directors (see also Riverside Partners).
Dr. Eagling brings to J-Pac and Doyen ...